m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG00899)
Name
22R-hydroxycholesterol
Synonyms
22beta-hydroxycholesterol; 22R-OHC
    Click to Show/Hide
Status
Investigative
Structure
Formula
C27H46O2
InChI
1S/C27H46O2/c1-17(2)6-11-25(29)18(3)22-9-10-23-21-8-7-19-16-20(28)12-14-26(19,4)24(21)13-15-27(22,23)5/h7,17-18,20-25,28-29H,6,8-16H2,1-5H3/t18-,20-,21-,22+,23-,24-,25+,26-,27+/m0/s1
InChIKey
RZPAXNJLEKLXNO-GFKLAVDKSA-N
PubChem CID
167685
TTD Drug ID
D0K4GK
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Oxysterols receptor LXR-alpha (NR1H3)
YTH domain-containing family protein 2 (YTHDF2)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Oxysterols receptor LXR-alpha (NR1H3) is a therapeutic target for 22R-hydroxycholesterol. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of 22R-hydroxycholesterol through regulating the expression of Oxysterols receptor LXR-alpha (NR1H3). [1], [2]
References
Ref 1 EGFR/SRC/ERK-stabilized YTHDF2 promotes cholesterol dysregulation and invasive growth of glioblastoma. Nat Commun. 2021 Jan 8;12(1):177. doi: 10.1038/s41467-020-20379-7.
Ref 2 Brain endogenous liver X receptor ligands selectively promote midbrain neurogenesis. Nat Chem Biol. 2013 Feb;9(2):126-33. doi: 10.1038/nchembio.1156. Epub 2012 Dec 23.